Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)

NCT02513472 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

258

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Neoplasm

Interventions

DRUG: Eribulin Mesylate
DRUG: Pembrolizumab

Sponsor

Eisai Inc.

Collaborators

[object Object]